Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (9) 9
male (9) 9
abridged index medicus (7) 7
risk factors (7) 7
adult (6) 6
aged (5) 5
cardiovascular disease (5) 5
diabetes (5) 5
diabetes mellitus (5) 5
female (5) 5
medicine, general & internal (5) 5
middle aged (5) 5
cardiovascular diseases (4) 4
cerebral infarction (4) 4
health risk assessment (4) 4
incidence (4) 4
myocardial infarction (4) 4
risk analysis (4) 4
type 2 diabetes (4) 4
clinical trials (3) 3
complications (3) 3
disease control (3) 3
endocrinology & metabolism (3) 3
health risks (3) 3
heart attacks (3) 3
hemoglobin (3) 3
hypoglycemia (3) 3
liraglutide (3) 3
motivation (3) 3
patients (3) 3
peptides (3) 3
randomization (3) 3
stroke (3) 3
aged, 80 and over (2) 2
agonists (2) 2
antipyrine - metabolism (2) 2
arteriosclerosis (2) 2
base-line (2) 2
blood pressure (2) 2
body mass index (2) 2
cardiovascular diseases - prevention & control (2) 2
cardiovascular outcomes (2) 2
care and treatment (2) 2
case-control studies (2) 2
cholesterol (2) 2
control methods (2) 2
diabetes mellitus, type 2 - complications (2) 2
diabetes mellitus, type 2 - drug therapy (2) 2
diabetic retinopathy (2) 2
disease (2) 2
disease prevention (2) 2
double-blind method (2) 2
drug dosages (2) 2
enzymes (2) 2
events (2) 2
fda approval (2) 2
gastrointestinal surgery (2) 2
glucagon (2) 2
glucagon-like peptide 1 (2) 2
half-life (2) 2
heart rate - drug effects (2) 2
hyperglycemia (2) 2
kidney (2) 2
kidney diseases (2) 2
kinetics (2) 2
lipids (2) 2
metabolism (2) 2
metoprolol - pharmacology (2) 2
microvasculature (2) 2
obesity (2) 2
pindolol - pharmacology (2) 2
reduction (2) 2
rifampin - pharmacology (2) 2
risk groups (2) 2
safety (2) 2
therapy (2) 2
2013 accf/aha guideline (1) 1
administration, oral (1) 1
adolescent (1) 1
adrenergic beta-antagonists - pharmacology (1) 1
albuminuria (1) 1
alcohol (1) 1
american-college (1) 1
analysis (1) 1
angina (1) 1
angina pectoris (1) 1
antibodies - blood (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - immunology (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antibodies; antibodies, monoclonal, humanized; anticholesteremic agents; cardiovascular diseases; cholesterol, ldl; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections, subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - immunology (1) 1
anticholesteremic agents - therapeutic use (1) 1
apolipoprotein-ciii (1) 1
appetite (1) 1
association (1) 1
association task-force (1) 1
atenolol - pharmacology (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
by Wiviott, Stephen D and Raz, Itamar and Bonaca, Marc P and Mosenzon, Ofri and Kato, Eri T and Cahn, Avivit and Silverman, Michael G and Zelniker, Thomas A and Kuder, Julia F and Murphy, Sabina A and Bhatt, Deepak L and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P.H and Ruff, Christian T and Gause-Nilsson, Ingrid A.M and Fredriksson, Martin and Johansson, Peter A and Langkilde, Anna-Maria and Sabatine, Marc S and DECLARE-TIMI 58 Investigators and DECLARE–TIMI 58 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
by Ridker, Paul M and Revkin, James and Amarenco, Pierre and Brunell, Robert and Curto, Madelyn and Civeira, Fernando and Flather, Marcus and Glynn, Robert J and Gregoire, Jean and Jukema, J. Wouter and Karpov, Yuri and Kastelein, John J.P and Koenig, Wolfgang and Lorenzatti, Alberto and Manga, Pravin and Masiukiewicz, Urszula and Miller, Michael and Mosterd, Arend and Murin, Jan and Nicolau, Jose C and Nissen, Steven and Ponikowski, Piotr and Santos, Raul D and Schwartz, Pamela F and Soran, Handrean and White, Harvey and Wright, R. Scott and Vrablik, Michal and Yunis, Carla and Shear, Charles L and Tardif, Jean-Claude and SPIRE Cardiovascular Outcome Inve and SPIRE Cardiovascular Outcome Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events... 
TRIALS | MEDICINE, GENERAL & INTERNAL | EVENTS | METAANALYSIS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
by Bohula, Erin A and Scirica, Benjamin M and Inzucchi, Silvio E and Inzucchi, Silvio and McGuire, Darren K and Keech, Anthony C and Keech, Anthony and Smith, Steven R and Smith, S and Kanevsky, Estella and Murphy, Sabina A and Leiter, Lawrence A and Dwyer, Jamie P and Dwyer, Jamie and Corbalan, Ramon and Hamm, Christian and Kaplan, Lee and Nicolau, Jose Carlos and Ophuis, Ton Oude and Ray, Kauski and Ray, Kausik K and Ruda, Mikhail and Spinar, Jindrich and Patel, S and Patel, R and Patel, Tushar and Miao, Wenfeng and Perdomo, Carlos and Francis, Bruce and Dhadda, Shobha and Bonaca, Marc P and Ruff, Christian T and Sabatine, Marc S and Wiviott, Stephen D and Satlin, Andrew and Brown, Conville and Brown, J and Budaj, Andrzej and Garcia-Castillo, Armando and Gupta, N and Gupta, Milan and Oude Ophuis, Ton and Weissman, Neil and White, Harvey D and White, A and White, J and Amerena, J and Arstall, M and Colquhoun, D and Jayasinghe, R and Lee, A and Lee, J and Lehman, R and Moses, R and Proietto, J and Purnell, P and Waites, J and Blombery, P and Cross, D and Worthley, M and d'Emden, M and Selvanayagam, J and Oqueli, RE and Whelan, A and Garrahy, P and de Looze, F and Ninio, D and Horowitz, J and William, M and Suranyi, M and Wittert, G and Le May, M and Pandey, AS and Vizel, S and Labonte, R and Beaudry, Y and Fortin, C and Bell, A and Kouz, S and St-Amour, É and Bata, I and St Maurice, F and Chehayeb, R and Constance, C and Wong, G and Hess, A and Liutkus, J and Poirier, P and Teitelbaum, I and Berlingieri, J and Cha, J and Hartleib, M and Heffernan, M and Twum-Barima, D and Pandith, V and Aronson, R and Goldenberg, R and Ajala, B and Jain, A and Ross, S and ... and CAMELLIA-TIMI61 Steering Comm and CAMELLIA-TIMI 61 Steering Committee Investigators
The Lancet, ISSN 0140-6736, 11/2018, Volume 392, Issue 10161, pp. 2269 - 2279
There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has... 
LIFE-STYLE INTERVENTION | MEDICINE, GENERAL & INTERNAL | THERAPY | LIRAGLUTIDE | REDUCTION | CARDIOVASCULAR OUTCOMES | WEIGHT-LOSS | BARIATRIC SURGERY | FOLLOW-UP | ASSOCIATION | Type 2 diabetes | Prevention | Clinical trials | Obesity | Analysis | Diabetic retinopathy | Heart attacks | Body weight | Cardiovascular disease | Diabetic neuropathy | Body weight loss | Risk factors | Body mass index | Randomization | Hyperglycemia | Vascular diseases | Motivation | Atherosclerosis | Hemoglobin | Remission | Diabetes mellitus (non-insulin dependent) | Appetite | Hypertension | Serotonin | Complications | Diabetes mellitus | Weight loss | Health risks | FDA approval | Hypoglycemia | Metabolism | Risk analysis | Patients | Disease control | Disease prevention | Weight control | Statistical models | Arteriosclerosis | Coronary vessels | Microvasculature | Lifestyles | Gastrointestinal surgery | Diabetes | Health risk assessment | Long-term effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4.